• Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact

Barry A. Friedman, PhD LLC

FDA Regulatory Compliance for the Pharmaceutical, Biotechnology and Medical Device Arenas

JUBILANT HOLLISTERSTIER, LLC RECEIVES WARNING LETTER (11/27/13)

December 19, 2013 By Barry Friedman Leave a Comment

FIRM FAILS TO ASSURE ADEQUATE USE OF SPORICIDAL AGENTS AND CLEANING SUPPLIES

Jubilant HollisterStier, Spokane, WA was audited by the FDA between April 15 and May 10, 2013.  The FDA reviewed the firm’s response from May 30 and noted that sufficient corrections actions were lacking.  The FDA also received additional correspondence dated July 12 and August 15, but believed that a Warning Letter was required.  Two Observations, both related to microbiology, were subsequently issued.  This Blog only discusses the second Observation.  The first Observation was reviewed in an earlier Blog.

The second citation cited (21 CFR 211.42(c)(10)(v) focuses upon provisions to ensure adequate use of sporicidal agents and the use of mops and wipes.  Observation 2(a) suggests that sporicidal agents are not required on aseptic filling line stainless steel, non-removable components, and the ISO 5 rigid barriers.  Observation 2(b) focuses upon the questions of “visually soiled” vs. sterile.  The FDA’s latest guidance on mops, disinfectants/sterilants, buckets, etc suggest that all of these items must be used as sterile when cleaning an Aseptic Processing Area (APA).

2.   “Your firm failed to assure an adequate system for cleaning and disinfecting aseptic processing areas and equipment (21 CFR 211.42(c)(10)(v)).

a)    For example, your firm’s SOP 101.74, “General Cleaning, Sanitization and Disinfection of Aseptic and Controlled Areas,” lacks provisions to ensure adequate use of sporicidal agents. According to SOP 101.74, sporicidal agents are not required on aseptic filling line stainless steel, non-removable components, and the ISO 5 rigid barriers. According to SOP 101.74, (b)(4) will be used to sanitize/clean stainless steel components in the aseptic or controlled areas.

In your response you state that SOP 402.12, “Controlled and Classified Area Out-of-Service Process” has been revised to include (b)(4) disinfection of aseptic fill-lines and non-removable ISO5 equipment and platforms when out-of-service activities require scrubs or street clothes. However, your response is inadequate because you failed to address the routine use of sporicidal agents.

b)      Your firm’s SOP 101.74, “General Cleaning, Sanitization and Disinfection of Aseptic and Controlled Areas,” also lacks adequate details on how many times mops and wipes can be used.

Your response is inadequate because you did not provide scientific data that the corrective actions implemented in SOP 101.74, “General Cleaning, Sanitization and Disinfection of Aseptic and Controlled Area” are adequate. While this SOP instructs staff to replace mops, wipes, and other supplies when visually soiled, it is unclear whether this revision will provide for acceptable standards of sanitization and disinfection in the controlled area.”

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)

Related

Filed Under: FDA Compliance, Microbiological Issues, Regulatory Compliance, Warning Letters Tagged With: 211.42(c)(10)(v), APA, aseptic processing area, cleaning supplies, disinfection, sanitization, sporcides, sporicidal agents, visually soiled

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

New Reader? Learn More

Connect With Me:

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Webinar Registration & Information

FREQUENTLY ASKED QUESTIONS:

FDA Form 483 Frequently Asked Questions

USP General Chapter

USP General Chapter 62, Part II

TOP OBSERVATIONS:

FDA’s CDER LISTING OF TOP NINETEEN OBSERVATIONS FOR 2014

FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

Top Posts:

Top Posts for 2012

Top Posts for 2013

Top Posts Year To Date

Recent Posts

  • Upcoming Microbiological Webinars
  • Microbiological Webinars
  • Microbiological Webinars 2020 (Upcoming)
  • General Chapter (USP<60>) on B. cepacia Complex to Issue December 1, 2019
  • Les Produits Chimiques B.G.R., Inc. Receives FDA Warning Letter (07/24/2018) for Failure to Perform Laboratory Testing

Categories

follow us in feedly
  • Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Thank You For Visiting Barry A. Friedman, PhD LLC - 2015

Welcome To My Blog!
Please enter your name and email below to receive my newsletter.
Your information will *never* be shared or sold to a 3rd party.